Gyre Therapeutics Valuation
| GYRE Stock | 11.75 1.16 8.99% |
At this time, the firm appears to be overvalued. Gyre Therapeutics retains a regular Real Value of USD10.92 per share. The prevalent price of the firm is USD11.75. Our model calculates the value of Gyre Therapeutics from evaluating the firm fundamentals such as Current Valuation of 1.08 B, return on asset of 0.1, and Return On Equity of -0.83 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Gyre Therapeutics' valuation include:
Price Book 17.5369 | Enterprise Value 1.1 B | Enterprise Value Ebitda 91.9055 | Price Sales 9.9292 | Enterprise Value Revenue 10.3269 |
Overvalued
Today
Please note that Gyre Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Gyre Therapeutics is based on 3 months time horizon. Increasing Gyre Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gyre stock is determined by what a typical buyer is willing to pay for full or partial control of Gyre Therapeutics. Since Gyre Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gyre Stock. However, Gyre Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.75 | Real 10.92 | Hype 11.71 | Naive 10.31 |
The real value of Gyre Stock, also known as its intrinsic value, is the underlying worth of Gyre Therapeutics Company, which is reflected in its stock price. It is based on Gyre Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Gyre Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Gyre Therapeutics helps investors to forecast how Gyre stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gyre Therapeutics more accurately as focusing exclusively on Gyre Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Gyre Therapeutics' intrinsic value based on its ongoing forecasts of Gyre Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Gyre Therapeutics' closest peers. If more than one evaluation category is relevant for Gyre Therapeutics we suggest using both methods to arrive at a better estimate.
Gyre Therapeutics Cash |
|
Gyre Valuation Trend
Comparing Gyre Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Gyre Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Gyre Therapeutics Total Value Analysis
Gyre Therapeutics is currently projected to have valuation of 1.08 B with market capitalization of 1.11 B, debt of 409 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gyre Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.08 B | 1.11 B | 409 K |
Gyre Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gyre Therapeutics has an asset utilization ratio of 97.35 percent. This indicates that the Company is making USD0.97 for each dollar of assets. An increasing asset utilization means that Gyre Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Gyre Therapeutics Ownership Allocation
Gyre Therapeutics has a total of 85.82 Million outstanding shares. Gyre Therapeutics retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 74.7 (percent) of Gyre Therapeutics outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Gyre Therapeutics Profitability Analysis
The company reported the previous year's revenue of 113.45 M. Net Loss for the year was (85.48 M) with profit before overhead, payroll, taxes, and interest of 0.Gyre Therapeutics Past Distributions to stockholders
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Gyre Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Gyre Therapeutics and how it compares across the competition.
About Gyre Therapeutics Valuation
The stock valuation mechanism determines Gyre Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Gyre Therapeutics. We calculate exposure to Gyre Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gyre Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 108.8 M | 114.3 M | |
| Pretax Profit Margin | (0.68) | (0.71) | |
| Operating Profit Margin | (0.59) | (0.62) | |
| Net Loss | (0.82) | (0.86) | |
| Gross Profit Margin | 0.96 | 1.01 |
A single share of Gyre Therapeutics represents a small ownership stake in the entity. As a stockholder of Gyre, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Gyre Therapeutics Dividends Analysis For Valuation
Please note that Gyre Therapeutics has scaled down on payment of dividends at this time. As of November 22, 2024, Retained Earnings is expected to decline to about (89.8 M). In addition to that, Earnings Yield is expected to decline to -0.06
There are various types of dividends Gyre Therapeutics can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Gyre shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Gyre Therapeutics directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Gyre pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Gyre Therapeutics by the value of the dividends paid out.
Gyre Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Gyre Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 65.8 M | |
| Quarterly Earnings Growth Y O Y | -0.705 |
Gyre Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Gyre Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Gyre we look at many different elements of the entity such as Gyre's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Gyre Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Gyre Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Gyre Therapeutics' worth.Complementary Tools for Gyre Stock analysis
When running Gyre Therapeutics' price analysis, check to measure Gyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gyre Therapeutics is operating at the current time. Most of Gyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gyre Therapeutics' price. Additionally, you may evaluate how the addition of Gyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |